PS
NTLA icon

Principal Securities’s Intellia Therapeutics NTLA Stock Holding History

Principal Securities’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-44
Closed -$760 – 2772
2025
Q3 		$760 Sell
44
-147
-77% -$1.81K ﹤0.01% 3459
2025
Q2 		$1.79K Buy
191
+102
+115% +$838 ﹤0.01% 3178
2025
Q1 		$1.04K Hold
89
– – ﹤0.01% 3203
2024
Q4 		$1.04K Sell
89
-480
-84% -$7.49K ﹤0.01% 3196
2024
Q3 		$11.7K Buy
569
+482
+554% +$11.1K ﹤0.01% 2366
2024
Q2 		$1.95K Sell
87
-25
-22% -$595 ﹤0.01% 2918
2024
Q1 		$3.08K Buy
112
+24
+27% +$667 ﹤0.01% 2756
2023
Q4 		$2.68K Buy
+88
New +$2.53K ﹤0.01% 2733

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Principal Securities's NTLA Position: Q4 2025 in Review

Principal Securities sold out of Intellia Therapeutics (NTLA) in Q4 2025, closing a stake of 44 shares — an estimated $760 sold.

Principal Securities first reported a position in NTLA in Q4 2023 and held it in 8 quarters. The position peaked at $11.7K in Q3 2024. 291 funds tracked by Wall St. Rank hold NTLA as of Q4 2025.

  • Principal Securities reported no remaining Intellia Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 44 Intellia Therapeutics shares in Q4 2025, an estimated $760.
  • Principal Securities first reported a position in Intellia Therapeutics in Q4 2023 and held it in 8 quarters.
  • Principal Securities's Intellia Therapeutics position peaked at $11.7K in Q3 2024.
  • 291 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.